Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients
All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients
Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile
The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future
CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.
'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.'
'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.'
In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment.
Safety
Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing.
Clinical Development Plans
Intellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit clinicaltrials.gov.
About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program
Intellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit clinicaltrials.gov (NCT05120830) for more details.
About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 ( KLKB1 ) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Forward-Looking Statements
This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027.
Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.
Intellia Contacts:
Investors:Brittany ChavesSenior Manager, Investor Relations
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
15 minutes ago
- USA Today
The businesses that are, and aren't, shifting production under Trump's tariffs
New York-based manufacturer Gear Motions purchases the majority of its parts from U.S. suppliers, with roughly 4% of inputs imported from other countries. It's a small fraction, but with a 10% base tariff in effect since early April, President and CEO Dean Burrows said his company, which specializes in custom cut and ground gears, will have to pass down those price increases to customers. That's not for lack of trying to find new suppliers. 'We have not been able to find a U.S. source that can make the product, and we have searched globally,' Burrows said. Tariffs are meant to fix that, with the Trump administration aiming to 'reverse the decades of globalization that has decimated our industrial base,' according to an April White House press release. But reviving the U.S. manufacturing base would take years, and economists have doubts that President Donald Trump's tariffs will be enough to bring it back to its former glory. Meanwhile, many U.S. manufacturers that rely on imports may be more likely to pass on tariff costs to consumers than reshore their supply chains. Nearly one-third of U.S. manufacturers' intermediate inputs are imported from other countries, according to a 2022 report from the Commerce Department. 'In the short run, it's going to hurt manufacturers. It's going to hurt the factory owners. It's going to hurt the workers,' said Nancy Qian, an economics professor at Northwestern's Kellogg School of Management. 'And that's on top of the pain the workers will feel when they go to the store and need to pay more for their imported (items).' Why shifting to US suppliers isn't always an easy solution Trump's tariffs are meant to position the U.S. as a 'global superpower in manufacturing' by drawing in new factories and manufacturing investments. 'The president has said early and often that the best way to avoid tariffs is to just come here and produce," Trump's top trade adviser, Peter Navarro, told CNBC in early April. 'We're going to get to a place where America makes stuff again.' But moving supply chains to the U.S. can be costly. Nearly two-thirds of 380 surveyed companies say building a new domestic supply chain would at least double their current costs, according to an April CNBC survey. Sixty-one percent said it would be more cost-effective to relocate to a lower-tariffed country. 'If the U.S. continues its focus on China, it will be successful in moving production out of China to some extent, but it won't move so much of it back to the U.S.,' Qian said. 'There are many other countries out there that can manufacture at costs lower than the U.S.' Even if tariffs boost U.S. manufacturing, it'll take years for new factories to get up and running. That could leave U.S. companies searching for domestic suppliers struggling in the meantime. Take 000Skin, a beauty company launched by Hannah Chang earlier this year. While 000Skin is based in New York, Chang has been sourcing the containers for her skin care products in China, where she says manufacturing capabilities are unmatched. 'I think people are not aware how much work and infrastructure even creating a plastic jar takes,' Chang said. But rising import costs from tariffs have thrown her for a loop. Chang has looked for alternative suppliers in the U.S., but says she has yet to find options that match the quality and price of what Chinese manufacturers can supply. She's considered shifting to a Mexican producer, but said it's been difficult finding one willing to work with smaller businesses. 'I'll probably just continue to look at China-based partners,' Chang said, adding that she's considering raising prices to cover at least some of the 30% tariff rate. Courtney Rivenbark looked into working with U.S. manufacturers when she created her apparel and jewelry brand, Coco Clem, in 2018. The high production costs turned her away, and she eventually pivoted to a partnership with a Chinese factory she said aligned with her ethical and environmental goals. 'China is just very advanced with their machines and equipment and technology,' Rivenbark said. 'The whole supply chain exists in China – the knits, the yard, the GOTS (Global Organic Textile Standard) certified organic cotton yarn.' After Trump announced new tariffs earlier this year, Rivenbark said she compared pricing from China with U.S. manufacturers. She said it would cost her three times more to create the same sweater in the U.S., and local manufacturers didn't have the technology to create certain garments in plus sizes. 'I would move (production to the U.S.) if the infrastructure was here,' Rivenbark said. But 'it's just so much more expensive. ... I'm not really interested in moving it outside of China because of a potential short-term policy switch.' How many factories, jobs are coming to the US? That's not to say tariffs aren't pressuring some businesses to increase their investments in the U.S. Whether those moves will lead to a dramatic influx of manufacturing jobs is another question. Cra-Z-Art – a New Jersey-based manufacturer that produces toys, activities and school supplies – in March announced plans to grow production space by 50% to 1.5 million square feet to combat the cost of tariffs. Lawrence Rosen, chairman of Cra-Z-Art, said it's too early to say how many jobs the move will create, but the company is looking to use automation 'wherever possible' to reduce direct labor costs. 'I need to control my 102-year-old company's destiny by controlling its future and not relying on global tariffs when things could change daily,' Lawrence said. 'By manufacturing in the USA, we save on freight, we save with automation. ... With automation, we can produce many of our products at a similar cost compared to increased costs with even 10% tariffs on freight.' A White House website claims Trump's policies have spurred trillions of dollars in new U.S. manufacturing investments that are 'fueling job growth, innovation, and opportunity across every corner of the country.' A number of those investments were in the works before Trump took office. A $5 billion investment from automaker Stellantis, for instance, includes plans to restart an idled plant in Belvidere, Illinois, to make trucks, a deal first announced in 2023. While there were talks of delays in 2024, the company in January confirmed that it would stick to the 2027 opening agreed to in union negotiations years prior. And a spokesperson for German medical technology company Siemens Healthineers, another company listed on the website, told USA TODAY that several of the initiatives included in its $150 million investment in new and expanded U.S. facilities have been underway for 'well over a year," although projects were accelerated to address rising economic and geopolitical uncertainty. Michael Strain, director of economic policy studies at the American Enterprise Institute, a conservative think tank, doesn't expect to see much reshoring tied to tariffs. 'For a business to set up a factory in the United States, that's a 10-year investment or longer,' Strain said. 'How can a business possibly know whether or not that would be profitable if tariff rates are changing every week?" Some data suggests the domestic manufacturing industry has actually taken a hit from tariffs, with trade policy uncertainty prompting some companies to tighten their purse strings. Economic activity in the manufacturing sector contracted in May for the third consecutive month to reach its lowest level since November, with both orders and output contracting, according to a survey by the Institute for Supply Management. Meanwhile, the manufacturing sector lost about 8,000 jobs between April and May despite an overall increase in employment, according to the Labor Department. Susan Helper, an economics professor at Case Western Reserve University in Ohio who served on the White House staff in both the Obama and Biden Administrations, believes tariffs can be a useful tool, but the uncertainty surrounding trade policy has been 'a real problem.' "I think what companies are doing is just not investing anywhere in anything and just waiting to see how things shake out,' she said.
USA Today
15 minutes ago
- USA Today
Tariffs are meant to boost US manufacturing. Is America ready?
Winton Machine, an Atlanta-based manufacturer, is desperate to hire. So far, there are few takers. CEO and co-founder Lisa Winton has been searching for a salesperson since March. A mechanist job has been open even longer, with less than a dozen applications over the past year – none of whom had the skillset required for the job. Winton has done what she can to attract workers, like forming a relationship with local technical colleges, offering applicants flexible hours and rehiring retirees. Still, keeping her staffing up has been a challenge. The push for more domestic manufacturing through tariffs, Winton worries, will only make matters worse. 'If more factories move into an area, who are they competing with? They're competing with other factories," she said. "Whether it be machinists or maintenance or assembly, all of the different types of jobs that are available – they have to come from somewhere.' President Donald Trump has said his tariffs, which range from a 10% baseline tariff on trade partners to 50% on steel imports, will have jobs and factories 'come roaring back.' 'The end game is to have production here. Any country that wants to produce here doesn't pay a tariff. That's the ultimate solution,' Trump's top trade adviser, Peter Navarro, told ABC News in early April. It's not clear that America is prepared for that shift. Building new manufacturing facilities can take up to 10 years, depending on the industry, and experts say the country's infrastructure isn't primed to handle additional factories. Meanwhile, a manufacturing labor shortage could mean new factories have a hard time filling roles. 'If the Trump administration's vision is to bring manufacturing back to America en masse – not just in a few sectors, but en masse – that vision isn't realistic," said Nancy Qian, an economics professor at Northwestern's Kellogg School of Management. Why building factories will take time It's not clear how many businesses will shift production to the U.S. because of tariffs. Those that do reshore face a lengthy process. 'Most companies do not make a decision to onshore or to build a new factory or plant lightly,' said Erin McLaughlin, a senior economist at the Conference Board, a nonprofit business-research group. 'This is something for most companies that they strategize many years in advance.' First, companies must figure out where to build. The location needs to be close to transportation corridors, good water supplies and on a stable electric grid – something easier said than done with current U.S. infrastructure, which earned a C in its 2025 report card from the American Society of Civil Engineers, according to McLaughlin. Then, companies must purchase the land, obtain proper permits and inspections, design their factory, purchase equipment and select a construction team. Only then can they start construction. The process generally takes three to 10 years, depending on the industry, McLaughlin said. Certain projects can be done in less time, although the timeline can be challenged by growing competition for sites with access to a stable electric grid, according to Jeff Bischoff, chief sales officer at Lexington, Kentucky-based designer-builder Gray. 'Power generation is not keeping up right now with demand,' Bischoff said. 'All the utilities are doing their best to try to keep up and get ahead of that. But it's a several-year process.' Trump has acknowledged that infrastructure changes will be necessary, and believes it would take roughly two years to get his vision for manufacturing up and running. 'You've got to build a thing called a factory. You have to build your energy. You have to do a lot of things,' Trump said on April 7, adding that he would give businesses approvals for electric plants in 'record timing.' But McLaughlin believes a two-year turnaround for bolstering the U.S. manufacturing sector could be optimistic. Even if executive orders speed up federal approvals, she said, factories would likely still need to worry about state and local permits. More complications could arise if the Trump administration continues to crack down on immigration, with roughly 20% of manufacturing workers in the U.S. foreign-born, according to labor market analytics firm Lightcast. An even higher share – roughly 30% – are foreign-born in construction. "We don't want to be over reliant on one trading partner for certain things,' McLaughlin said. But 'I don't think the U.S. is prepped and primed for everything to be manufactured here.' Are tariffs worth the pain? Trump says the ultimate fruits of tariffs will be worth the pain. Experts disagree. Why manufacturers are struggling to hire Trump's push for more factories comes after a dramatic decline in manufacturing jobs. After accounting for roughly 22% of total nonfarm employment in 1979, manufacturing work makes up just 8% today. Even if tariffs were able to eliminate the entire U.S. trade deficit in manufacturing, that would still only bump that share up to about 10% of employment – still less than half of its share in the late 1970s, according to Robert Lawrence, a Harvard professor of international trade and investment and author of 'Behind the Curve: Can Manufacturing Still Provide Inclusive Growth?' 'Even in its most successful form, this is barely noticeable,' Lawrence said. Other experts warn that even that level of growth could exacerbate the hiring challenges manufacturers face today. Manufacturers have been struggling to fill jobs for years, including during a post-pandemic construction boom, when supply chain issues pushed more manufacturers to build facilities closer to home. The number of manufacturing establishments in the U.S. increased by more than 11% between the first quarter of 2019 and the second quarter of 2023, according to a 2024 report from Deloitte. Despite the growth, manufacturing jobs have remained essentially flat since 2019, discounting a pandemic-era dip. That's partially due to automation; factories today need fewer workers. But nearly half of manufacturers say attracting and retaining talent has been a major challenge, according to a first-quarter survey from the National Association of Manufacturers. Bureau of Labor Statistics data shows there were 381,000 manufacturing job openings as of April. By 2033, manufacturing could have 1.9 million unfilled jobs – roughly half of open positions – due to a skills and applicant gap, according to Deloitte. 'We absolutely do not have enough people ready to take these jobs,' said Rachel Sederberg, senior economist at Lightcast. 'That is going to be a very significant challenge if more and more manufacturing – or more and more of anything – comes back to the U.S.' One issue is that manufacturing workers are aging out of the workforce. Just over one-third of manufacturing employees in the U.S. are 55 or older and nearing retirement, according to a recent report from Lightcast, which is expected to make the shortage even more acute. And attracting new talent to backfill these positions hasn't been easy. As factories turn to more automation, manufacturers say they're having trouble finding talent with the right skillset to manage the more advanced technology. 'Not every manufacturing job today requires a degree, but every single manufacturing job today requires skills,' said Carolyn Lee, executive director of the Manufacturing Institute, a nonprofit focused on workforce development and education within the industry. Lee said obtaining those skills can take anywhere from a day or two for a forklift certification to up to four years of education and apprenticeship programs for maintenance technicians, one of the most in-demand manufacturing jobs today. There are some signs of renewed interest in trade jobs. Enrollment in public two-year institutions that focus on vocational programs was up 14% year-over-year in 2024, outpacing the 3% growth in public four-year schools, according to a May 12 Wells Fargo report. But Lightcast found there are still not enough students learning relevant skills to keep up with job demand. For instance, there were just 400 machinist program completions in Texas in 2023 compared to roughly 16,000 related job openings in the state. Research suggests manufacturing's reputation as dirty and dangerous has made the industry less appealing to younger Americans, especially amid a period of low unemployment. The Deloitte report says 'a different set of expectations' among millennial and Generation Z workers, many of whom were pushed to go to college instead of working in the trades, has made it difficult for manufacturers to attract and retain workers. 'The consensus among American manufacturers is this generation of Americans just don't want these jobs anymore," said Qian of Northwestern. Fear of lower wages may also be keeping workers away. Manufacturing work today can pay well, and some research finds it tends to pay better than other sectors that don't require college degrees. But as of 2018, the average hourly earnings for manufacturing employees fall short of average overall employee earnings, according to the Bureau of Labor Statistics. What kind of jobs would more manufacturing create? There's a reason so many American companies rely on factories abroad; operating in the U.S. tends to be more expensive. For one, labor costs are higher. Take the average annual machine operator salary, which is nearly $45,000 in the U.S. compared to $15,000 in China and less than $5,000 in Vietnam, according to the Reshoring Institute, a nonprofit that supports expanded U.S. manufacturing. And tariffs are expected to hike production costs for many domestic manufacturers, since companies will need to pay more for inputs shipped in from other countries. That could leave manufacturers increasingly turning toward automation to trim costs. 'If you need to pay anyone you employ as a factory worker an average of $36 an hour with benefits, then you are inclined to hire very few of them and instead buy automated equipment and robots,' said Farok Contractor, a professor at Rutgers' management and global business department. Winton of Winton Machine said she's already seeing an increased demand for automation from her company, which designs and produces factory automation for manufacturers in HVAC, aerospace, construction and other industries. Winton still expects to see jobs created if manufacturing gets a boost through tariffs. She just believes automation will allow fewer, high-quality positions as opposed to a large influx of manual labor. Already, manufacturing is relying on more college-educated workers; nearly 32% of civilian manufacturing workers had at least a bachelor's degree in 2023, up from 22% in 2006, according to a USA TODAY analysis of the Census Bureau's American Community Survey data. 'I need the people to build all the parts and pieces and the engineers to design and the software to build this factory automation,' Winton said. 'I think we have the people. Do we have the skillset? That's the question.'
Business Insider
32 minutes ago
- Business Insider
The CEO building the 'Ikea of factories' wants to democratize semiconductor production
In his 1986 book "Engines of Creation," engineer K. Eric Drexler — often called the godfather of nanotechnology — made a prediction. "The coming era of molecular machines will mean the end of many limits: the limit of scarcity, the limit of slow development, the limit of ignorance enforced by the lack of tools," he wrote. Reading those words a few years later, when he was 16, Matthew Putman started thinking. "Our bodies work as these little micro-machines where you have ribosomes and enzymes and things that are working and replicating and making things all the time, but our factories work the way that they've worked for the last hundred years," Putman told Business Insider he thought at the time. He wondered how a world would look "where you don't have large assembly lines, you don't have smokestacks, you instead just make things so perfectly," he said. Putman became fascinated by the possibilities of machines that are "atomically precise." It wasn't until the recent AI boom, however, that the idea really took off with fabrication plants. Putman, now 50, is the CEO of Brooklyn-based Nanotronics, which he cofounded with his father in 2010. The company started out building microscopes and tools to detect defects in semiconductors, among other materials. Now, it builds small, modular semiconductor manufacturing plants called Cubefabs. While the biggest fabs in the country are often millions of square feet in size, Cubefabs measure anywhere from 25,000 square feet for the smallest units up to about 60,000 square feet for a full-sized fab. They're adaptable, and the company says they can be assembled in under a year in most places on Earth. They're also smart — thanks to the power of AI — so they can self-monitor their production and improve in real time, the company said. And they're relatively cheap, costing a minimum of $30 to $40 million, compared to large fabs that can cost billions to build. With President Donald Trump back in the White House and pledging to reinvigorate US manufacturing, a new opening has emerged for Nanotronics — even as sweeping tariffs challenge companies that produce or depend on semiconductors. Putman says that in the long term, the tariffs will bolster domestic innovation. Tariffs "should be a wake-up call — a push to create something better than what either the US or China has done before," he told BI in a video interview from the Nanotronics headquarters in Brooklyn Navy Yard. "If we get this right, American innovation won't just protect our future — it could help redefine global progress in a way that benefits humanity." Putman says compact, modular factories are exactly that. "Your factory should be incredibly small," Putman said, gesturing to the room behind him. "Eventually, it could be the size of this room." The 'Ikea of factories' Semiconductor manufacturing has surged since the launch of ChatGPT. Global annual revenue for the industry is expected to reach more than $1 trillion by 2030, according to McKinsey & Company. In the US, despite legislation subsidizing domestic semiconductor production, fabs are more expensive to construct and maintain than those built in places like mainland China and Taiwan, McKinsey says. The US also suffers from a shortage of qualified labor, which can delay construction timelines, according to the firm. To attempt to solve some of these issues, Nanotronics teamed up with architecture firm Rogers Partners and engineering firm Arup to design compact factories. Each one runs with 37 people, but Putman says the ideal setup is four factories — about 180 workers total — which allows them to scale up without halting production. "It's like the Ikea of factories," Putman said. The company has raised $182 million to date from firms including Peter Thiel's Founders Fund. Cubefabs can be used to produce chips that span a range of uses across electronics applications, electric vehicles, and photodetectors for cube satellites, Putman said. "The more precise we make things, the more abundance we bring to the world," he said. "The business of making things grow bigger and bigger starts small — molecular small." Building on the foundational research of scientist Philippe Bove — now chief scientist at Nanotronics — the company also uses gallium oxide — a type of semiconductor that can handle more power than traditional materials like silicon — to produce advanced chips. The company plans to have its first installation set up in New York within the next 18 months. "These fabs do not require billions in capital expenditure or large populations of highly trained workers," Putman told BI in a follow-up email. "The vision is that any region — whether in the Global South or the United States — should be able to produce what it needs locally."
